Annual Meeting of Stockholders. April 26, 2005

Transcription

1 Annual Meeting of Stockholders April 26, 2005

2 Research Update Peter S. Kim President, Merck Research Laboratories April 26, 2005

3 Forward-Looking Statements This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.

4 No Duty to Update The information contained in this presentation was current as of April 26, While this presentation remains on the Company's website, the Company assumes no duty to update the information to reflect subsequent developments. Consequently, the Company will not update the information contained in the presentation, and investors should not rely upon the information as current or accurate after April 26, 2005.

5 Proof-of-Concept Efficacy Study: HPV 16 (Median 40 Months after Completion of Vaccine Regimen) Endpoint HPV 16 Infection + CIN HPV 16 Related CIN 1 HPV 16 Related CIN 2/3 Placebo Cases Mao C et. al. ICAAC. Nov 2004.

6 Proof-of-Concept Efficacy Study: HPV 16 (Median 40 Months after Completion of Vaccine Regimen) Endpoint Placebo Cases HPV 16 Vaccine Cases Vaccine Efficacy HPV 16 Infection + CIN % HPV 16 Related CIN % HPV 16 Related CIN 2/ % Mao C et. al. ICAAC. Nov 2004.

7 Gardasil Phase II Study Results! 90% reduction in combined incidence of persistent infection and related clinical disease from HPV 6,11,16 or 18! Results recently published in The Lancet Oncology! Submission anticipated 2H05

8 RNA Interference (16 Sept., 2004) Produced with support from Merck & Co., Inc. and Alnylam Pharmaceuticals Inc.

9 ! Approved by FDA July 2004

10 ! Approved by FDA July 2004! Approved by FDA April 2005

11 Submission Updates*! PROQUAD: Pediatric Combination Vaccine Submitted to FDA in August 2004 * As of April 22, 2005

12 Submission Updates*! PROQUAD: Pediatric Combination Vaccine Submitted to FDA in August 2004! Muraglitazar: Diabetes Submitted to FDA in December 2004 * As of April 22, 2005

13 Submission Updates*! PROQUAD: Pediatric Combination Vaccine Submitted to FDA in August 2004! Muraglitazar: Diabetes Submitted to FDA in December 2004! ROTATEQ: Rotavirus Vaccine Submitted to FDA in April 2005 * As of April 22, 2005

14 Submission Updates*! PROQUAD: Pediatric Combination Vaccine Submitted to FDA in August 2004! Muraglitazar: Diabetes Submitted to FDA in December 2004! ROTATEQ: Rotavirus Vaccine Submitted to FDA in April 2005! ZOSTAVAX: Varicella-Zoster Virus Vaccine Anticipate submission to FDA 2Q05 * As of April 22, 2005

15 Submission Updates*! PROQUAD: Pediatric Combination Vaccine Submitted to FDA in August 2004! Muraglitazar: Diabetes Submitted to FDA in December 2004! ROTATEQ: Rotavirus Vaccine Submitted to FDA in April 2005! ZOSTAVAX: Varicella-Zoster Virus Vaccine Anticipate submission to FDA 2Q05! GARDASIL: HPV Vaccine Anticipate submission to FDA 2H05 * As of April 22, 2005

16 Submission Updates*! PROQUAD: Pediatric Combination Vaccine Submitted to FDA in August 2004! Muraglitazar: Diabetes Submitted to FDA in December 2004! ROTATEQ: Rotavirus Vaccine Submitted to FDA in April 2005! ZOSTAVAX: Varicella-Zoster Virus Vaccine Anticipate submission to FDA 2Q05! GARDASIL: HPV Vaccine Anticipate submission to FDA 2H05! MK-0431: Diabetes Anticipate submission to FDA in 2006 * As of April 22, 2005

17 Submission Updates*! PROQUAD: Pediatric Combination Vaccine Submitted to FDA in August 2004! Muraglitazar: Diabetes Submitted to FDA in December 2004! ROTATEQ: Rotavirus Vaccine Submitted to FDA in April 2005! ZOSTAVAX: Varicella-Zoster Virus Vaccine Anticipate submission to FDA 2Q05! GARDASIL: HPV Vaccine Anticipate submission to FDA 2H05! MK-0431: Diabetes Anticipate submission to FDA in 2006! Gaboxadol: Insomnia Anticipate submission to FDA late 2006-early 2007 * As of April 22, 2005

18 Increasing Number of Compound Alliances New Compounds PROBIODRUG SCHERING- PLOUGH TAISHO ARENA ACTELION AMRAD KINEXIS METHYLGENE NEUROGEN NICOX SUNESIS ACUMEN ALNYLAM ATON BMS DOV INTERCELL KYORIN LUNDBECK METABASIS ONO NASTECH PIERRE-FABRE SUNESIS TRANSTECH VERTEX

19 Increased Pipeline Value through Alliances! ONO-2506 Phase II stroke compound! SAHA Phase II compound for the treatment of cancer

20 MRL Boston

21 Merck Pipeline Phase I March 1, 2004 February 15, 2005 AIDS c-2507 Alzheimer s Disease, c-7617 Alzheimer s Disease c-9138 Arthritis, c-7198 Alzheimer s Disease, c-7617 Arthritis, c-9101 Arthritis c-5997 Cancer, c-8585 Arthritis, c-4462 Cancer, VX-680 Atherosclerosis, c-8834 CINV, c-9280 Diabetes, c-3347 Diabetes, c-0730 HIV Vaccine Endocrine, c-0239 Multiple Sclerosis, c-6448 Endocrine, c-0302 Obesity, c-2624 Endocrine, c-7717 Obesity, c-5093 Pain c-1246 Psychiatric Disease, c-9054 Respiratory Disease, c-3193 Glaucoma, c-3859 Obesity, Nastech PYY3-36 Osteoporosis, c-3578 Pain, c-8928 Pain, c-6740 Pain, c-1246 Parkinson s Disease, c-6161 Psychiatric Disease, DOV Urinary Incontinence, c-4699 Urinary Incontinence, c-0172 Only the most advanced compound with a specific mechanism in a given therapeutic area is shown. Back-ups not included. Preclinical = GLP studies Licensed (Pipeline)

22 Merck Pipeline Phase II March 1, 2004 February 15, 2005 Alzheimer s Disease, c-9136 AIDS, c-1605 Cancer (CTCL), SAHA Alzheimer s Disease, c-9136 Obesity, c-2735 Arthritis, c-9787 PONV, c-9280 Arthritis, c-4462 Pediatric Vaccine Atherosclerosis, c-8834 Respiratory Disease, c-3885 Atherosclerosis, c-1602 Urinary Incontinence, c-3048 Cancer (CTCL), SAHA Diabetes, c-3347 HIV Vaccine Multiple Sclerosis, c-6448 Obesity, c-2624 Obesity, c-2735 Obesity, c-5093 Pediatric Vaccine Psychiatric Disease, c-9054 Respiratory Disease, c-3193 Respiratory Disease, c-3885 Stroke, ONO 2506 Only the most advanced compound with a specific mechanism in a given therapeutic area is shown. Back-ups not included. Preclinical = GLP studies Licensed (Pipeline)

23 Merck Pipeline March 1, 2004 Preclinical Phase I Phase II Phase III Antibacterials AIDS, c-2507 Alzheimer s Disease, c-9136 Anxiety Alzheimer s Disease, c-9138 Cancer (CTCL), SAHA Arthritis Alzheimer s Disease, c-7617 Obesity, c-2735 HPV and related cervical cancer and genital warts Gardasil Rotavirus Gastroenteritis RotaTeq Atherosclerosis Arthritis, c-5997 PONV, c-9280 Shingles, Zoster Vaccine Cancer Arthritis, c-4462 Pediatric Vaccine Zostavax Diabetes Atherosclerosis, c-8834 Respiratory Disease, c-3885 Pediatric Vaccine ProQuad Diabetes, c-3347 Glaucoma Urinary Incontinence, c-3048 Osteoporosis Pain Parkinson s Disease Vaccines HIV Vaccine Multiple Sclerosis, c-6448 Obesity, c-2624 Obesity, c-5093 Pain, c-1246 Psychiatric Disease, c-9054 Respiratory Disease, c-3193 Insomnia Gaboxadol Diabetes, MK U.S. Submissions Cardiovascular Vytorin Arthritis/Analgesia Arcoxia Only the most advanced compound with a specific mechanism in a given therapeutic area is shown. Back-ups not included. Preclinical = GLP studies Licensed (Pipeline)

24 Merck Pipeline February 15, 2005 Preclinical Phase I Phase II Phase III Alzheimer s Disease Alzheimer s Disease, c-7617 AIDS, c-1605 Antiviral Arthritis, c-7198 Alzheimer s Disease, c-9136 Antibacterials Arthritis, c-9101 Arthritis, c-9787 Arthritis Cancer, c-8585 Arthritis, c-4462 Atherosclerosis Cancer, VX-680 Atherosclerosis, c-8834 Cancer CINV, c-9280 Atherosclerosis, c-1602 Cardiovascular Disease Diabetes, c-0730 Cancer (CTCL), SAHA HPV and related cervical cancer and genital warts Gardasil Rotavirus Gastroenteritis RotaTeq Shingles, Zoster Vaccine Zostavax Insomnia Gaboxadol Diabetes, MK-431 Diabetes Endocrine, c-0239 Diabetes, c-3347 Glaucoma Endocrine, c-0302 Immunology Endocrine, c-7717 Insomnia Glaucoma, c-3859 Osteoporosis Obesity, Nastech PYY3-36 Pain Osteoporosis, c-3578 Respiratory Disease Pain, c-8928 Vaccines Pain, c-6740 HIV Vaccine Multiple Sclerosis, c-6448 Obesity, c-2624 Obesity, c-2735 Obesity, c-5093 Pediatric Vaccine Psychiatric Disease, c U.S. Submissions Osteoporosis Fosamax Plus D Pediatric Vaccine ProQuad Diabetes Muraglitazar Only the most advanced compound with a specific mechanism in a given therapeutic area is shown. Pain, c-1246 Respiratory Disease, c-3193 Parkinson s Disease, c-6161 Respiratory Disease, c-3885 Psychiatric Disease, DOV Stroke, ONO 2506 Urinary Incontinence, c-4699 Urinary Incontinence, c-0172 Back-ups not included. Preclinical = GLP studies Licensed (Pipeline)

25 Annual Meeting of Stockholders

26 1-800-CALLMRK ( )